Updates to our Terms of Use

We are updating our Terms of Use. Please carefully review the updated Terms before proceeding to our website.

Friday, May 24, 2024 | Back issues
Courthouse News Service Courthouse News Service

Drug Antitrust

MINNEAPOLIS - Boehringer Ingelheim conspired with Barr Pharmaceuticals et al. to delay introduction of a generic form of the stroke drug Aggrenox, costing consumers millions of dollars, a union health care fund claims in a federal antitrust class action.

Categories / Uncategorized

Subscribe to Closing Arguments

Sign up for new weekly newsletter Closing Arguments to get the latest about ongoing trials, major litigation and hot cases and rulings in courthouses around the U.S. and the world.

Loading...